Amendment of the terms and conditions of the bond completed; Bondholders can
convert bonds into shares

EQS-News: aap Implantate AG / Key word(s): Bond
Amendment of the terms and conditions of the bond completed; Bondholders can
convert bonds into shares

23.05.2024 / 19:05 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Notice to the Holders of the Mandatory Convertible Bond 2023/2028

(ISIN: DE000A351ZH9 / WKN: A351ZH)

aap Implantate AG announces today that the resolution adopted in the vote
held without a meeting from March 26, 2024, to March 28, 2024, to cancel the
vesting period regarding the conversion of the bonds and to allow a
first-time conversion right in the period of 14 days before May 31, 2024,
has become effective. After the expiry of the statutory challenge period,
the resolution on the amendment of the terms and conditions of the Bonds
("Bond
Terms") was deposited with the depositary Clearstream Banking Frankfurt and
attached to the global certificate. The announcement of the completion of
the terms and conditions of the bond is also expected to be published in the
Federal Gazette on 24 May 2024.

As a result of the change in the terms and conditions of the bonds, the
bondholders are now entitled to convert their bonds into shares of aap
Implantate AG during the exercise period in accordance with the terms and
conditions of the bond. The last exercise day of the actual exercise period
is Wednesday, May 29, 2024.

In order to exercise the conversion right, the bondholder must submit a duly
completed and signed declaration to the conversion agent or its custodian
bank during normal business hours on a business day using a form available
on the website of aap Implantate AG under
https://www.aap.de/investoren/wandelschuldverschreibung . Declarations of
exercise are irrevocable.

The exercise of the conversion right is subject to the delivery of the bonds
for which the conversion right is to be exercised to the conversion agent no
later than 29 May 2024, namely by delivery (transfer) of the bonds to the
account of the conversion agent at Clearstream Frankfurt.

IMPORTANT INFORMATION

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE
AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SUBSCRIBE FOR ANY SECURITIES.
THE DISTRIBUTION OF THIS ANNOUNCEMENT MAY BE SUBJECT TO LEGAL RESTRICTIONS
IN CERTAIN JURISDICTIONS. PERSONS READING THIS NOTICE MUST INFORM THEMSELVES
ABOUT THESE RESTRICTIONS AND COMPLY WITH THESE RESTRICTIONS

---------------------------------------------------------------------------------------------------

aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market -
All German Stock Exchanges -

About aap Implantate AG

aap Implantate AG is a global medical technology company headquartered in
Berlin, Germany. The company develops, manufactures, and markets products
for traumatology. In addition to the innovative anatomical plate system
LOQTEQ®, the IP-protected portfolio includes a wide range of perforated
screws. In addition, aap Implantate AG has an innovation pipeline with
promising development projects, such as antibacterial silver coating
technology and magnesium-based implants. These technologies address critical
and not yet adequately solved problems in traumatology. In Germany, aap
Implantate AG sells its products directly to hospitals, purchasing groups
and affiliated clinics, while on an international level, it primarily uses a
broad network of distributors in around 25 countries. In the USA, the
company and its subsidiary aap Implants Inc. are focusing on a sales
strategy via distribution agents. The shares of aap Implantate AG are listed
in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For
more information, please visit our website at www.aap.de.

There may be technical rounding differences in the figures presented in this
press release, which do not affect the overall statement.

Forward-Looking Statements

This release may contain forward-looking statements based on the current
expectations, assumptions and forecasts of the Management Board and
information currently available to it. The forward-looking statements are
not to be understood as guarantees of future developments and results
referred to therein. Various known and unknown risks, uncertainties and
other factors could cause the actual results, financial condition,
development, or performance of the Company to differ materially from the
estimates given herein. These factors also include those described by aap in
published reports. Forward-looking statements therefore speak only as of the
date on which they are made. We undertake no obligation to update the
forward-looking statements made in this release or to conform them to future
events or developments.


Contact:

If you have any questions, please contact: aap Implantate AG; Rubino Di
Girolamo, Chairman/ CEO, Lorenzweg 5; 12099 Berlin.

Tel.: +49 (0)30 75019 - 170; Fax: +49 (0)30 75019 - 290; Email:
r.digirolamo@aap.de


---------------------------------------------------------------------------

23.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        aap Implantate AG
                   Lorenzweg 5
                   12099 Berlin
                   Germany
   Phone:          +49 (0) 30 75 019-0
   Fax:            +49 (0) 30 75 019-111
   E-mail:         info@aap.de
   Internet:       www.aap.de
   ISIN:           DE000A3H2101
   WKN:            A3H210
   Listed:         Regulated Market in Frankfurt (General Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1910167

End of News EQS News Service
---------------------------------------------------------------------------

1910167 23.05.2024 CET/CEST